

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/510,627	· 06/20/2005	Kiyoshi Ando	09617.0001	4183	
22852 FINNEGAN, H	7590 05/01/200 IENDERSON, FARAE	EXAMINER			
LLP 901 NEW YORK AVENUE, NW WASHINGTON, DC 20001-4413			BELYAVSKYI, MICHAIL A		
			ART UNIT	PAPER NUMBER	
	,	1644			
				•	
			MAIL DATE	DELIVERY MODE	
			05/01/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		App	lication No.	Applicant(s)	Applicant(s)			
			510,627	ANDO ET AL.	ANDO ET AL.			
Office Action Summary		Exar	niner	Art Unit				
		Mich	ail A. Belyavskyi	1644				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
WHIC - Exte after - If NC - Failt Any	IORTENED STATUTORY PERIOD FOR CHEVER IS LONGER, FROM THE MAIL ensions of time may be available under the provisions of 37 r SIX (6) MONTHS from the mailing date of this communic D period for reply is specified above, the maximum statutor ure to reply within the set or extended period for reply will, reply received by the Office later than three months after the patent term adjustment. See 37 CFR 1.704(b).	ING DATE C CFR 1.136(a). In ation. by period will apply by statute, cause t	OF THIS COMMUNICA no event, however, may a rep and will expire SIX (6) MONTH he application to become ABAN	ATION. ly be timely filed IS from the mailing date of this NDONED (35 U.S.C. § 133).				
Status								
1)⊠	Responsive to communication(s) filed o	n <i>08 Februar</i>	v 2005.					
	ra) ☐ This action is FINAL . 2b) ☒ This action is non-final.							
3)								
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposit	ion of Claims							
5) 6) 7)	Claim(s) 1-20 is/are pending in the applied 4a) Of the above claim(s) is/are well claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) 1-20 are subject to restriction as	rithdrawn fron						
Applicat	ion Papers							
10)□	The specification is objected to by the ExThe drawing(s) filed on is/are: a)[Applicant may not request that any objection Replacement drawing sheet(s) including the The oath or declaration is objected to by	accepted to the drawing correction is r	g(s) be held in abeyance equired if the drawing(s)	e. See 37 CFR 1.85(a). is objected to. See 37 C	• •			
Priority (under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.								
2)	the of References Cited (PTO-892) the of Draftsperson's Patent Drawing Review (PTO-9) mation Disclosure Statement(s) (PTO/SB/08)	948)	5) Notice of Info	Mail Date rmal Patent Application				
Pape	r No(s)/Mail Date		6)					

Application/Control Number: 10/510,627

Art Unit: 1644

≑.

DETAILED ACTION

1. Applicant's amendment, filed 02/08/05 is acknowledged.

Claims 1-20 are pending.

Restriction Requirement

- 2. Restriction to one of the following inventions is required under 35 U.S.C. § 121:
- I. Claims 1, 6-10, drawn to a method of diagnosing leukemia, classified in Class 435, subclass 7.1.
- II. Claims 2, 6-10, drawn to a method for discriminating leukemia from pre-leukemia or aleukemic malignant blood disease, classified in Class 435, subclass 7.1.
- III. Claims 3, 6-10, drawn to a method for discriminating aplastic anemia from SCGP, classified in Class 435, subclass 7.1.
- IV. Claims 4, 6-10, drawn to a method for diagnosing the engraftment state of the hematopoietic stem cells after transplantation, classified in Class 435, subclass 7.1.
- V. Claims 5, 6-10, drawn to a method of diagnosing GVHD, classified in Class 435, subclass 7.1.
- VI. Claims 11-15, and 18-20 drawn to diagnostic agent for leukemia, comprising antibody reacting with SCGF, and hybridoma which produced monoclonal antibody, classified in Class 530, subclass 387.9 and 388.1, class 435 subclass 346.
- VII. Claims 16 and 17, drawn to a diagnostic kit, classified in Class 435, subclass 810.
- 3. Groups I-V are different methods. These inventions are different with respect to ingredients, method steps, and endpoints which require non-coextensive searches; therefore, each method is patentably distinct.

Art Unit: 1644

4. Groups VI-VII are different products. These inventions differ with respect to their structures and physicochemical properties, which require non-coextensive searches; therefore each product is patentably distinct.

- 5. Groups VI and I-V are related as product and process of using. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the antibody of Group I can be used for affinity purification, in addition to the recited methods.
- 6. These inventions are distinct for the reasons given above. In addition, they have acquired a separate status in the art as shown by different classification and/or recognized divergent subject matter. Further, even though in some cases the classification is shared, a different field of search would be required based upon the structurally distinct products recited and the various methods of use comprising distinct method steps. Moreover, a prior art search also requires a literature search. It is an undue burden for the examiner to search more than one invention. Therefore restriction for examination purposes as indicated is proper.
- 7. The examiner has required restriction between product and process claims. If applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the

Art Unit: 1644

product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

- 8. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).
- 9. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.
- 10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michail Belyavskyi whose telephone number is 571/272-0840 The examiner can normally be reached Monday through Friday from 9:00 AM to 5:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571/272-0841.

The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

MICHAIL BELYAVSKYI, PH.D. PATENT EXAMINER

4/27/07